Summary
"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring. This will enable patients and health experts to identify the most effective course of therapy.
The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem.
To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process.
Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."
The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem.
To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process.
Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101136379 |
| Start date: | 01-12-2023 |
| End date: | 31-05-2028 |
| Total budget - Public funding: | 10 060 452,50 Euro - 9 999 252,00 Euro |
Cordis data
Original description
"This project aims to create a multi-scale patient-specific human virtual twin for patients who are eligible for CAR T cell therapy, which can be extended to cellular immunotherapies in general. The virtual twin will be fully integrated into the ecosystem under the Digital Europe Programme and will be available as a research-use-only prototype in relevant application environments with technology readiness level 6. The virtual twin will support decision-making throughout the patient's journey, from diagnosis to pre-treatments, cellular immunotherapy, and late patient monitoring. This will enable patients and health experts to identify the most effective course of therapy.The virtual twin for cellular immunotherapies will take multi-scale modelling to the next level by providing methodological concepts for integrating ""living drugs"" such as CAR T cells into the human virtual twin ecosystem.
To achieve this goal, the project builds on existing data models for hematological malignancies and multiple myeloma (MM) to create a virtual twin for CAR T cell therapy for MM patients. The implementation process follows software development principles for software as medical devices, ensuring the exploitation of the research-use-only prototype. Patient's, SSH, gender differences, and other stakeholders' perspectives are fully integrated into the design, specification, and implementation process.
Throughout the implementation process, a modular software architecture and extensible ontologies/terminologies are utilized, making the reference model easily transferable to other indications that can be treated with CAR T cell therapy or other cellular immunotherapies. Overall, the CERTAINTY virtual twin will provide decision support for patients and health experts, improving the effectiveness of cellular immunotherapies and advancing precision medicine."
Status
SIGNEDCall topic
HORIZON-HLTH-2023-TOOL-05-03Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Coördinator)
-
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN
-
| EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION
-
| F. HOFFMANN-LA ROCHE AG
-
| HEALTHTREE FOUNDATION INC
-
| INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA
-
| INSTITUT CURIE
-
| MYELOMA PATIENTS EUROPE AISBL
-
| Masarykova univerzita - Masarykova university (MU)
-
| SINGLERON BIOTECHNOLOGIES GMBH
-
| STEINBEISSER PROJECT MANAGEMENT UG (HAFTUNGSBESCHRANKT)
-
| TRINETX ONCOLOGY GMBH
-
| UNIVERSITAET LEIPZIG
-
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
-
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT